PubRank

Anthony Letai

Author PubWeight™ 133.26‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The landscape of somatic copy-number alteration across human cancers. Nature 2010 31.88
2 An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005 22.40
3 Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006 10.29
4 Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 2003 6.78
5 Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 2007 5.02
6 BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 2007 4.55
7 Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 2011 4.46
8 Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci 2009 3.54
9 A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005 3.41
10 Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 2010 2.61
11 Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell 2012 2.51
12 Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov 2012 2.47
13 BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood 2007 2.12
14 Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Res 2007 2.10
15 Targeting the B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol 2012 2.09
16 Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes. Proc Natl Acad Sci U S A 2010 1.91
17 High mitochondrial priming sensitizes hESCs to DNA-damage-induced apoptosis. Cell Stem Cell 2013 1.86
18 P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Blood 2011 1.77
19 MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts. J Cell Biol 2009 1.72
20 KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol 2013 1.68
21 Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood 2012 1.58
22 BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response. Mol Cell 2013 1.48
23 Mitochondria: gatekeepers of response to chemotherapy. Trends Cell Biol 2013 1.44
24 Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res 2008 1.40
25 BH3 profiling in whole cells by fluorimeter or FACS. Methods 2013 1.40
26 BH3 profiling--measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett 2012 1.27
27 ABT-199: taking dead aim at BCL-2. Cancer Cell 2013 1.24
28 Parkin selectively alters the intrinsic threshold for mitochondrial cytochrome c release. Hum Mol Genet 2009 1.22
29 BH3-only proteins are part of a regulatory network that control the sustained signalling of the unfolded protein response sensor IRE1α. EMBO J 2012 1.17
30 Regulation of Bcl-2 family proteins by posttranslational modifications. Curr Mol Med 2008 1.16
31 Designed BH3 peptides with high affinity and specificity for targeting Mcl-1 in cells. ACS Chem Biol 2014 1.07
32 Rational design of therapeutics targeting the BCL-2 family: are some cancer cells primed for death but waiting for a final push? Adv Exp Med Biol 2008 0.97
33 The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell 2016 0.87
34 BCL2 suppresses PARP1 function and nonapoptotic cell death. Cancer Res 2012 0.86
35 BH3-only proteins and their effects on cancer. Adv Exp Med Biol 2010 0.83
36 Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition. Leuk Lymphoma 2013 0.81
37 iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry. Biol Chem 2016 0.81
38 Who put the "A" in Atg12: autophagy or apoptosis? Mol Cell 2011 0.79
39 Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER+ breast cancer. Breast Cancer Res 2013 0.77
40 BCL-2 inhibition: stemming the tide of myeloid malignancies. Cell Stem Cell 2013 0.77
41 Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia. J Clin Invest 2016 0.75